Agenus Inc (AGEN) Stock Price, Quote & News

Company Profile

Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 674 4400

Fax: 781 674 4200

Website: www.agenusbio.com

Address:

3 Forbes Road, Lexington, United States

73DTigerBl00D Feb. 6 at 2:36 AM

$AGEN but this isnt my sword

0 · Reply

2_logs_higher Feb. 6 at 1:11 AM

$AGEN no creditials needed for ceo, cfo, chairman of bod, so maybe anyone can apply for new opening in france not knowing french or any kols or the understanding why a p3 is needed or os data. maybe IR with spare time could do the job and taste wine on the side

0 · Reply

2_logs_higher Feb. 6 at 12:13 AM

$AGEN will bot + bal get over the finish line before trump makes the cure sell for commodity prices?

1 · Reply

pedmac2000 Feb. 6 at 12:03 AM

$AGEN new job in France to support expanded AAC access for the investigational combination of #BOT + #BAL across colorectal cancer, ovarian cancer, and soft-tissue sarcomas.

0 · Reply

pedmac2000 Feb. 5 at 11:42 PM

$AGEN didn’t Garo say once When our PPS was much higher than today That it would go 2 logs higher? Hence your name

0 · Reply

2_logs_higher Feb. 5 at 9:58 PM

$AGEN

1 · Reply

MC_Hunter Feb. 5 at 9:00 PM

$AGEN useless management

0 · Reply

73DTigerBl00D Feb. 5 at 7:57 PM

$SPY And together we are extraordinary $AGEN

0 · Reply

BakerBrother Feb. 5 at 7:54 PM

$AGEN earth to Agenus IR You have 2 phase 3 to trials Might be worth adding the one in France Sort trial by phase here: https://www.agenusbio.com/clinical-trials

0 · Reply

Biotechguy21 Feb. 5 at 7:28 PM

$AGEN full steam ahead for this pos!

0 · Reply

Agenus Inc. (AGEN) Discusses Zydus Collaboration, Global Manufacturing Expansion, and Patient Access Initiatives Transcript

Jan 21, 2026, 7:30 AM EST - 16 days ago

Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab

Jan 20, 2026, 6:24 PM EST - 16 days ago

Agenus to Host First 2026 Stakeholder Webcast

Jan 15, 2026, 8:30 AM EST - 22 days ago

Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S.

Jan 15, 2026, 7:01 AM EST - 22 days ago

Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness

Jan 12, 2026, 7:30 AM EST - 25 days ago

France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas

$Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC$

Dec 23, 2025, 8:05 AM EST - 6 weeks ago

Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC

Dec 4, 2025, 1:43 AM EST - 2 months ago

Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript

Nov 19, 2025, 4:01 PM EST - 2 months ago

Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL

Nov 18, 2025, 8:41 AM EST - 2 months ago

Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France's AAC

Nov 10, 2025, 7:30 AM EST - 3 months ago

Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances

Nov 5, 2025, 1:47 PM EST - 3 months ago

Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report

$Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025$

Oct 17, 2025, 8:00 AM EDT - 4 months ago

Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025

Oct 16, 2025, 7:48 AM EDT - 4 months ago

Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights

$France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer$

Sep 9, 2025, 7:43 AM EDT - 5 months ago

France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer

Sep 5, 2025, 8:52 AM EDT - 5 months ago

Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025, 2:04 PM EDT - 5 months ago

Agenus Inc. (AGEN) Virtual Stakeholder Briefing Call (Transcript)

Aug 26, 2025, 9:37 AM EDT - 5 months ago

Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight

Aug 19, 2025, 7:30 AM EDT - 6 months ago

Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025

Aug 11, 2025, 7:30 AM EDT - 6 months ago

Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress

Jul 31, 2025, 7:30 AM EDT - 6 months ago

Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report

$Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025$

Jul 25, 2025, 12:46 PM EDT - 6 months ago

Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025

$Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3$

Jul 7, 2025, 8:55 AM EDT - 7 months ago

Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3

Jun 17, 2025, 7:30 AM EDT - 8 months ago

Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology

Jun 10, 2025, 1:30 PM EDT - 8 months ago

Agenus Announces Virtual Annual Shareholders Meeting

Jun 4, 2025, 2:38 PM EDT - 8 months ago

Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang

Jun 3, 2025, 7:00 AM EDT - 8 months ago

Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the US

May 30, 2025, 7:30 AM EDT - 9 months ago

Agenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal Cancer

May 23, 2025, 3:09 PM EDT - 9 months ago

Agenus: Big On BOT/BAL As Cash Burn And Catalysts Collide

May 15, 2025, 10:40 AM EDT - 9 months ago

Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025

May 12, 2025, 2:46 PM EDT - 9 months ago

Agenus Inc. (AGEN) Q1 2025 Earnings Call Transcript

May 12, 2025, 7:30 AM EDT - 9 months ago

Agenus Reports Q1 2025 Financial Results and Key Business Updates

May 12, 2025, 7:20 AM EDT - 9 months ago

Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer

Apr 29, 2025, 7:30 AM EDT - 10 months ago

Agenus to Provide Corporate Update and First Quarter 2025 Financial Report

Apr 28, 2025, 3:30 PM EDT - 10 months ago

Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR

Apr 25, 2025, 1:05 PM EDT - 10 months ago

Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025

Apr 23, 2025, 12:05 PM EDT - 10 months ago

Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025

Mar 25, 2025, 4:40 PM EDT - 11 months ago

Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025

Mar 19, 2025, 7:30 AM EDT - 11 months ago

Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation

Mar 11, 2025, 10:39 AM EDT - 11 months ago

Agenus Inc. (AGEN) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 7:30 AM EDT - 11 months ago

Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program

Feb 26, 2025, 4:48 PM EST - 1 year ago

Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications

Feb 25, 2025, 2:30 PM EST - 1 year ago

Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference

Feb 25, 2025, 8:26 AM EST - 1 year ago

Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Feb 24, 2025, 8:33 AM EST - 1 year ago

Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting

Feb 23, 2025, 7:38 PM EST - 1 year ago

CORRECTING and REPLACING Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Feb 12, 2025, 1:00 PM EST - 1 year ago

Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

$Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas$

Jan 29, 2025, 12:37 PM EST - 1 year ago

Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Jan 22, 2025, 2:48 PM EST - 1 year ago

Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease

Dec 18, 2024, 7:30 AM EST - 1 year ago

Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers

73DTigerBl00D Feb. 6 at 2:36 AM

$AGEN but this isnt my sword

0 · Reply

2_logs_higher Feb. 6 at 1:11 AM

0 · Reply

2_logs_higher Feb. 6 at 12:13 AM

$AGEN will bot + bal get over the finish line before trump makes the cure sell for commodity prices?

1 · Reply

pedmac2000 Feb. 6 at 12:03 AM

$AGEN new job in France to support expanded AAC access for the investigational combination of #BOT + #BAL across colorectal cancer, ovarian cancer, and soft-tissue sarcomas.

0 · Reply

pedmac2000 Feb. 5 at 11:42 PM

$AGEN didn’t Garo say once When our PPS was much higher than today That it would go 2 logs higher? Hence your name

0 · Reply

2_logs_higher Feb. 5 at 9:58 PM

$AGEN

1 · Reply

MC_Hunter Feb. 5 at 9:00 PM

$AGEN useless management

0 · Reply

73DTigerBl00D Feb. 5 at 7:57 PM

$SPY And together we are extraordinary $AGEN

0 · Reply

BakerBrother Feb. 5 at 7:54 PM

$AGEN earth to Agenus IR You have 2 phase 3 to trials Might be worth adding the one in France Sort trial by phase here: https://www.agenusbio.com/clinical-trials

0 · Reply

Biotechguy21 Feb. 5 at 7:28 PM

$AGEN full steam ahead for this pos!

0 · Reply

BakerBrother Feb. 5 at 7:13 PM

$AGEN how come this Phase 3 randomized trial doesn’t get any air time? https://clinicaltrials.gov/study/NCT06346197?term=Leon%20Berard%20botensilimab&rank=1

2 · Reply

neversurrender2024 Feb. 5 at 6:38 PM

$AGEN oops.....going lower ...all time lows by april...

0 · Reply

AAAGenBot Feb. 5 at 6:36 PM

$AGEN Another trial got updated - NCT06268015 - It likely enrolled the needed 16 patients - need more investigators like Nicolas Devito - he also provided some updates while it was still recruiting.

1 · Reply

2_logs_higher Feb. 5 at 6:24 PM

$AGEN Guessing WS is not impressed with the 2M shares purchased using back door accounting at $7.

1 · Reply

73DTigerBl00D Feb. 5 at 6:08 PM

$SPY $AGEN

0 · Reply

2_logs_higher Feb. 5 at 4:24 PM

$AGEN & $INKT $PTIX Articles like this make one wonder how much G pissed off the FDA and how long they will hold a grudge. Maybe the FDA should just say, once G departs, we will approve. Nothing soon for PTIX as a result of this article. https://www.statnews.com/2026/02/04/psilocybin-depression-psychedelic-drug-fast-track-blocked/

1 · Reply

2_logs_higher Feb. 5 at 4:21 PM

$AGEN Dhan Chand likes this: https://www.linkedin.com/posts/bernard-a-fox-phd-2aa885b_worldcancerday-finishcancer-activity-7424950266476675072-x_Sw?utm_source=li_share&utm_content=feedcontent&utm_medium=g_dt_web&utm_campaign=copy

0 · Reply

BakerBrother Feb. 5 at 2:09 PM

$AGEN putting my short MSTR profit into this.

0 · Reply

73DTigerBl00D Feb. 5 at 1:10 AM

$AGEN TIGER BLOOD

0 · Reply

73DTigerBl00D Feb. 5 at 1:04 AM

$SPY $AGEN

1 · Reply

Biotechguy21 Feb. 4 at 9:49 PM

$AGEN can someone explain to me what’s the new excuse for this pos stock and team?

0 · Reply

73DTigerBl00D Feb. 4 at 9:47 PM

$AGEN i know i got a bad reputation…

0 · Reply

Market Cap	98.28M
Revenue (ttm)	103.46M
Net Income (ttm)	-227.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	5.37
Profit Margin	-219.61%
Debt to Equity Ratio	-0.12

Volume	490,700
Avg Vol	719,582
Day's Range	N/A - N/A
Shares Out	34.01M
Stochastic %K	12%
Beta	1.62
Analysts	Sell
Price Target	$12.33